[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Robyn T. Domsic, MD, MPH\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":73},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,46],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100567794","phase-2-intralesional-injection-of-sts-in-treatment-of-calcinosis-100567794",false,"NCT06672822","Intralesional Injection of STS in Treatment of Calcinosis","An Open Label Evaluation of Intralesional Injection of Sodium Thiosulfate in the Treatment of Cutaneous or Tendon Calcinosis in Connective Tissue Disease","STSINJ","Inclusion Criteria:\n\n* Clinical diagnosis of systemic sclerosis, mixed connective tissue disease or inflammatory myopathy\n* Must be over 18 years of age\n* Participants must be competent to give informed consent\n* Participants must have radiographic evidence (xray or ultrasound) of calcinosis.\n* Participants must need symptomatic relief\n\nExclusion Criteria:\n\n• Pregnant women will be excluded","ALL","18 Years",{"count":20,"type":21},20,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","The specific objective of this study is to perform a small, open-label study to assess the safety and efficacy of intralesional, subcutaneous injection of STS on calcinosis symptoms and lesion size in systemic sclerosis (SSc), mixed connective tissue disease (MCTD) and dermatomyositis (DM) patients. Injection will be guided by ultrasound, lesion size assessed by ultrasound, and symptom burden by patient-reported outcome measures.",[27,28,29,30],"Systemic Sclerosis (SSc)","Dermatomyositis","Mixed Connective Tissue Disease (MCTD)","Calcinosis",[32],"calcinosis","RECRUITING","2026-05-03",{"date":36,"type":37},"2026-05-05","ACTUAL",{"date":39,"type":37},"2025-03-17",{"date":41,"type":21},"2029-05-01",{"name":43,"class":44},"Robyn T. Domsic, MD, MPH","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":22,"phases":56,"briefSummary":58,"conditions":59,"keywords":60,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":72},"100567987","the-apollo-device-in-systemic-sclerosis-for-the-management-of-fatigue-raynaud-phenomenon-and-quality-of-life-100567987","NCT06675344","The Apollo Device in Systemic Sclerosis for the Management of fatiguE, Raynaud Phenomenon and qualiTy of Life","A Randomized, Double-blind, Clinical Trial of the Apollo Device in Systemic Sclerosis for the Management of fatiguE, Raynaud Phenomenon and qualiTy of Life (ASScERT-QoL)","ASScERT-QoL","Inclusion Criteria:\n\n1. Age ≥ 18 years\n2. Ability to provide written informed consent,\n3. Diagnosis of SSc, as defined by the 2013 ACR\u002FEULAR classification of SSc64 with a positive ANA\n4. Baseline score ≥55 on the FACIT-Fatigue scale,\n5. Presence of Raynaud phenomenon with ASRAP-SF severity of T-score ≥40,\n6. Steady daily doses and any immunosuppressive medication, vasodilators or other medications used to treat pulmonary hypertension, antidepressants and anxiolytic use for 4 weeks prior to baseline\n7. Currently owns and operates an iOS or Android smart phone regularly\n8. Ability to comply with the clinical visits schedule and the study-related procedures.\n\nExclusion Criteria:\n\n1. History of sympathectomy or stellate ganglion block\n2. History of Botox injections to the digits within the last 3 months\n3. Diabetes mellitus\n4. Major surgery within 8 weeks\n5. Hospitalization for any reason within four weeks of the study baseline visit\n6. Active malignancy\n7. Pregnant or breastfeeding women,\n8. End-stage renal disease (estimated glomerular filtration rate \\\u003C 15 mL\u002Fmin\u002F1.73m2) or on dialysis,\n9. Hepatic insufficiency as defined by function worse than Child-Pugh Class B\n10. Medication exclusions:\n\n    1. actively prescribed standing doses of beta-blockers,\n    2. actively prescribed standing doses of sedatives, hypnotics, opioids, benzodiazepines or anti-psychotic medications.",{"count":55,"type":21},160,[57],"NA","The purpose of this study it to test the efficacy of a wearable device to improve symptom management and maximize qualify of life in systemic Sclerosis (SSc) patients in a randomized trial. Specifically, we will evaluate if the Apollo Neuro device may improve the two specific symptoms highest ranked by patients as affecting qualify of life (fatigue, Raynaud phenomenon) as co-primary outcomes.",[27],[61,62,63],"Scleroderma","Raynaud Phenomenon","fatigue","2026-01-07",{"date":66,"type":37},"2026-01-08",{"date":68,"type":37},"2025-01-06",{"date":70,"type":21},"2028-09",{"name":43,"class":44},4,""]